Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Dec 6, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-update
TL;DR
Innate Pharma filed a 6-K, confirming 20-F filings and providing corporate details. Nothing major, just housekeeping.
AI Summary
Innate Pharma S.A. filed a Form 6-K on December 6, 2024, reporting on its activities. The filing includes information about the company's principal executive office located at 117 Avenue de Luminy, Marseille, France, and confirms it files annual reports under Form 20-F. Exhibits referenced include Exhibit 99.1, which contains statements from Dr. Sonia Quaratino and Dr. Michel Azoulay.
Why It Matters
This filing provides an update on Innate Pharma's regulatory reporting and corporate information, which is crucial for investors to stay informed about the company's compliance and operational details.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily contains corporate information and references to other exhibits, rather than announcing significant new developments.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- 117 Avenue de Luminy, Marseille, France (location) — Principal executive office
- Dr Sonia Quaratino (person) — Chief Medical Officer of Innate Pharma S.A.
- Dr. Michel Azoulay (person) — Chief Medical Officer of the Institute for Follicular Lymphoma
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that Innate Pharma S.A. is required to disclose to the public under French law or its listing requirements, including referencing exhibits like 99.1.
Where is Innate Pharma S.A.'s principal executive office located?
Innate Pharma S.A.'s principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma S.A. file annual reports under Form 20-F or Form 40-F?
Innate Pharma S.A. indicates that it files annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
This Form 6-K was filed on December 6, 2024.
What specific exhibits are mentioned in the filing?
The filing mentions Exhibit 99.1, which includes quotes from Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma S.A., and Dr. Michel Azoulay, Chief Medical Officer of the Institute for Follicular Lymphoma.
Filing Stats: 308 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-12-06 06:00:19
Filing Documents
- a241206-6kiph.htm (6-K) — 13KB
- exhibit991-241206.htm (EX-99.1) — 21KB
- exhibit992-241206.htm (EX-99.2) — 13KB
- 0001598599-24-000095.txt ( ) — 48KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date December 6, 2024 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive Officer